Emergent BioSolutions (EBS) Payables (2016 - 2025)
Historic Payables for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $57.4 million.
- Emergent BioSolutions' Payables fell 3076.0% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.4 million, marking a year-over-year decrease of 3076.0%. This contributed to the annual value of $60.9 million for FY2024, which is 8841.99% down from last year.
- Emergent BioSolutions' Payables amounted to $57.4 million in Q3 2025, which was down 3076.0% from $63.7 million recorded in Q2 2025.
- In the past 5 years, Emergent BioSolutions' Payables registered a high of $1.1 billion during Q1 2023, and its lowest value of $57.4 million during Q3 2025.
- Moreover, its 5-year median value for Payables was $166.8 million (2021), whereas its average is $327.4 million.
- Per our database at Business Quant, Emergent BioSolutions' Payables soared by 67386.61% in 2023 and then plummeted by 8961.39% in 2025.
- Emergent BioSolutions' Payables (Quarter) stood at $160.5 million in 2021, then soared by 560.93% to $1.1 billion in 2022, then tumbled by 50.42% to $525.9 million in 2023, then tumbled by 88.42% to $60.9 million in 2024, then decreased by 5.75% to $57.4 million in 2025.
- Its Payables was $57.4 million in Q3 2025, compared to $63.7 million in Q2 2025 and $58.1 million in Q1 2025.